Therapy News and Research

RSS

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

31 Mar 2010

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta Incorporated today announced that the Company has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development.

31 Mar 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010

SANUWAVE Health reports net loss of $2.7M for three months ended December 31, 2009

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, reports its financial results for the fourth quarter and full year ended December 31, 2009, and on its progress for the year.

31 Mar 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

T-cell cytolytic activity may be effective in clearing HBV infection

Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) poses a treatment challenge. In Western Europe and the United States, chronic HBV infection has been found in 6%󈝺% of HIV-positive patients and this co-infection is well known to be associated with increased liver-related morbidity and mortality. However, factors associated with HBV surface antigen (HbsAg) loss in HIV and HBV co-infected patients remain unclear.

31 Mar 2010

Panel of experts endorse effectiveness of Mirasol PRT System for preventing GVHD

CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, today announced that a panel of medical and scientific experts have endorsed the effectiveness of the Mirasol® Pathogen Reduction Technology System for replacing gamma irradiation, the current standard of care for preventing transfusion-related Graft vs. Host Disease in platelet recipients.

31 Mar 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

Bioheart presents cutting edge therapies at 2010 Translational Regenerative Medicine Forum

Bioheart, Inc., announced today that Dr. Karl E. Groth, the Company's Chairman and CEO will speak at the 2010 Translational Regenerative Medicine Forum in Winston-Salem, North Carolina, on April 8. Dr. Groth will discuss Bioheart's cell therapies for Congestive Heart Failure.

31 Mar 2010

Study comparing Plasma Disc Decompression with epidural steroid injections for lumbar disc herniation

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today the publication of an important clinical trial demonstrating that patients treated with ArthroCare's Plasma Disc Decompression (PDD) products experienced reduced pain and better quality of life scores compared to patients treated with the current standard care, epidural steroid injections.

31 Mar 2010

Plant-based system could help improve lives of hemophilic patients

Hemophilia, a disease linked with legends of European monarchs, frail heirs and one flamboyant charlatan called Rasputin, still afflicts many people today.

31 Mar 2010

Optometrists and dietitians are important part of health care team

For people with diabetes, proper nutrition can have a far-reaching effect on their health and wellness. They also have a higher risk of developing vision problems. March is National Nutrition Month and Save Your Vision Month, and the American Dietetic Association (ADA) and American Optometric Association (AOA) would like to remind people that optometrists and registered dietitians are an important part of the health care team.

31 Mar 2010

Massage Envy opens Leesburg clinic and Gainesville clinic

This week, Massage Envy, the nation's largest provider of therapeutic massage, opens the doors of two new clinics in the Washington, DC metro area - Leesburg, VA and Gainesville, VA. Massage Envy currently serves over 27,000 members throughout the nation's capital and the addition of the Northern Virginia locations brings the total to 21 clinics in the greater Baltimore/Washington, DC-area.

31 Mar 2010

MITA supports FDA's interest to reduce exposure to medical radiation, minimize medical errors

The Medical Imaging & Technology Alliance, the leading association representing the manufacturers, innovators and developers of medical imaging and radiation therapy systems, today said it is supportive of the Food and Drug Administration's ongoing interest to further reduce exposure to unnecessary medical radiation and minimize medical errors.

31 Mar 2010

Renewed set of national policy guidelines to control diarrhoeal disease in Kenya

Today the Ministry of Public Health and Sanitation, together with the Department of Family Health (Division of Child and Adolescent Health), unveiled a renewed set of national policy guidelines to redouble diarrhoeal disease management and control efforts by putting proven interventions to work within the country's health system.

31 Mar 2010

Bright light therapy box for SAD, depression, bipolar disorder and sleep problems

Alaska Northern Lights manufactures a bright light therapy box that aids in treating chronic health problems such as seasonal affective disorder (SAD), depression, bipolar disorder and sleep problems. Sufferers of SAD, a form of clinical depression, include up to 25 percent of those living in northern latitudes who experience varying degrees of SAD during winter months when there is less natural light. Night shift workers are also susceptible to SAD which affects over one third of the population, or about 10.8 million Americans.

31 Mar 2010

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches and widespread uptake of novel oral anticoagulants will drive the venous thromboembolism drug market to nearly double from $2.9 billion in 2008 to more than $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

31 Mar 2010

$Notch pathway could aid treatment of osteoporosis, fractures and arthritis$

Notch pathway could aid treatment of osteoporosis, fractures and arthritis

Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.

31 Mar 2010

Vantage Communications becomes agency of record for ImThera Medical

Vantage Communications, an award-winning global PR firm, today announced that it is the agency of record for ImThera Medical, Inc. Within a few months, Vantage Communications successfully promoted ImThera and its medical device technology with original coverage garnered in top-tier publications such as Neurotech Insights, ENToday, The Gray Sheet, Sleep Review, Respiratory & Sleep Management, Respiratory Therapy, Medical Device Daily, and medGadget.

31 Mar 2010

Therapy News and Research

RXi Pharmaceuticals reports net loss of 28% for 2009

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

SANUWAVE Health reports net loss of $2.7M for three months ended December 31, 2009

Rosetta Genomics reports revenues of $150,000 for full-year 2009

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

T-cell cytolytic activity may be effective in clearing HBV infection

Panel of experts endorse effectiveness of Mirasol PRT System for preventing GVHD

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Bioheart presents cutting edge therapies at 2010 Translational Regenerative Medicine Forum

Study comparing Plasma Disc Decompression with epidural steroid injections for lumbar disc herniation

Plant-based system could help improve lives of hemophilic patients

Optometrists and dietitians are important part of health care team

Massage Envy opens Leesburg clinic and Gainesville clinic

MITA supports FDA's interest to reduce exposure to medical radiation, minimize medical errors

Renewed set of national policy guidelines to control diarrhoeal disease in Kenya

Bright light therapy box for SAD, depression, bipolar disorder and sleep problems

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

Notch pathway could aid treatment of osteoporosis, fractures and arthritis

Vantage Communications becomes agency of record for ImThera Medical

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News